Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Email

NCI Experimental Therapeutics Program (NExT)

Overview:

  • A peer-reviewed program to support the discovery and development of promising agents for cancer therapeutics towards/through the clinic
  • Resources available encompass the end-to-end process: early discovery, candidate selection, IND enabling (cGMP, GLP PK/Tox, filing), FIH, Phase I/II (operated through CTEP)
  • NExT does NOT award grants to the applicants, but rather supports their projects via NCI contracts to advance approved projects in a milestone-driven manner.  Clinical trials may be supported through NCI-funded clinical trial networks
  • Results/products are returned to the applicant PIs and used to support further development by the applicants or in partnership with NCI.
  • Applicants retain ownership of their existing IP– new IP may be shared
  • Currently, NExT application cycles are occurring on an ad hoc basis

 

Typical NExT collaboration sectors that occur at each stage in the pipeline

 

Eligibility Requirements:

  • Researchers in academia, non-profit, and industry
  • Institutions need to have a majority presence in the US
  • Foreign entities/collaborations require additional justifications when applying
  • Only 2 submissions allowed (initial and a re-submission)

About the NExT Program

Email